Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jan 31;8(5):8717-8725.
doi: 10.18632/oncotarget.14427.

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

Alessandro Russo  1 , Tindara Franchina  1 , Giuseppina Rosaria Rita Ricciardi  1 , Caterina Fanizza  2 , Antonino Scimone  1 , Giuseppe Chiofalo  1 , Antonio Giordano  3   4 , Vincenzo Adamo  1
Affiliations
Comparative Study

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

Alessandro Russo et al. Oncotarget. .

Abstract

Epidermal Growth Factor Receptor (EGFR) mutated Non Small Cell Lung Cancers (NSCLCs) are a molecularly subgroup of patients with peculiar clinic-pathological characteristics. Previous studies have suggested a possible interaction between oncogene status and metastatic behavior in non squamous NSCLCs with conflicting results. The aim of this study was to compare the different metastatic patterns, at baseline and during the course of the disease, in a cohort of 137 Caucasian patients with non-squamous NSCLC according to the EGFR mutational status and survival differences according to the different metastatic behavior. We observed unique metastatic distributions between EGFR-mutated and EGFR wild type non-squamous NSCLCs. These data support the hypothesis that tumor bio-molecular characteristics and genotype may influence the metastatic process in NSCLC and might help the development of enrichment strategies for tumor genotyping in these tumors, especially in the presence of limited tissue availability.

Keywords: EGFR WT; EGFR mutations; NSCLC; brain metastases; metastatic spread.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

no potential conflicts of interest declared.

Figures

Figure 1
Figure 1. Metastatic pattern at baseline according to the EGFR mutational status
Figure 2
Figure 2. Median OS according to the EGFR mutational status in the overall population
Figure 3
Figure 3. Median OS in patients with Brain Metastases (BMs) according to the EGFR mutational status
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015;6:26814–25. doi: 10.18632/oncotarget.4254. - DOI - PMC - PubMed
    1. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31:1097–104. - PMC - PubMed
    1. Cancer Genome Atlas Research. Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50. - PMC - PubMed
    1. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014. pp. e353–65. - PubMed

Publication types

MeSH terms